Single-dose (177)Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial
单剂量 (177)Lu-PSMA-617 序贯帕博利珠单抗维持治疗转移性去势抵抗性前列腺癌患者：一项开放标签、剂量扩展的 I 期试验
期刊:Lancet Oncology
影响因子:35.9
doi:10.1016/S1470-2045(23)00451-5
Aggarwal, Rahul; Starzinski, Stephanie; de Kouchkovsky, Ivan; Koshkin, Vadim; Bose, Rohit; Chou, Jonathan; Desai, Arpita; Kwon, Daniel; Kaushal, Samuel; Trihy, Lauren; Rastogi, Medini; Ippisch, Robin; Aslam, Maya; Friedlander, Terence; Feng, Felix; Oh, David; Cheung, Alexander; Small, Eric; Evans, Michael; Fong, Lawrence; Hope, Thomas A
